Impedimed Ltd has released a press release.
Appendix 4C - Quarter ended 30 September 2017
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Earlier from Impedimed
- Shipments of SOZO with L-Dex Commence in the US
- New Study Reports Superior Clinical Outcomes Utilising L-Dex
- Appendix 4E - year ended 30 June 2017
- Heart Failure 510(k) Application for SOZO Submitted to FDA
- US FDA 510(k) Clearance Issued for SOZO with L-Dex
Later from Impedimed
- Multi-year Exclusive Distribution Agreement Signed
- 2018 Reimbursement Amounts Published by CMS
- L-Dex Abstracts to be Presented at Breast Cancer Symposium
- US FDA 510(k) Clearance Issued for CHF Monitoring with SOZO
- Appendix 4C - Quarter ended 31 December 2017
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed